MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze CTMX →
    • FindStock Picks / Stock Screener
    • Value · CTMXIntrinsic Value Calculator
    • Invest · CTMXInvestment Case
    • Hold · CTMX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CTMX stock logo

CTMX

CytomX Therapeutics, Inc.

$2.03
-0.02
 (-0.98%)
Exchange:  NASDAQ
Market Cap:  442.55M
Shares Outstanding:  137.936M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Sean A. McCarthy
Full Time Employees:  69
Address: 
151 Oyster Point Boulevard
South San Francisco
CA
94080
US
Website:  https://www.cytomx.com
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

CTMX full analysis

16/03/2026

Hey everyone, welcome back to the channel! Today, we’re diving deep into a really intriguing biotech stock, CytomX Therapeutics, ticker CTMX. If you’re into innovative cancer treatments and high-growth potential stocks, you’re gonna want to stick around for this comprehensive analysis. We’ll cover everything from their financials to their pipeline, recent performance, and whether this stock could be a buy for your portfolio. Let’s get started! First off, let’s set the stage. CytomX Therapeutics is a biopharmaceutical company focused on…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
CTCTMX logoCTMXCytomX Therapeutics, Inc.442.5M——-29.7%
MDMDXG logoMDXGMiMedx Group, Inc.445.1M——-9.7%
DMDMAC logoDMACDiaMedica Therapeutics Inc.445.1M——-143.8%
CACAPR logoCAPRCapricor Therapeutics, Inc.439.6M——-50.8%
OCOCS logoOCSOculis Holding AG435.8M——-42.4%
ANANL logoANLAdlai Nortye Ltd.453.8M——-9.2%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue101,214138,10376,201
Gross Profit101,214138,10376,201
EBITDA5,49833,861-15,754
Operating Income-6,48424,995-22,364
Net Income-56931,869-17,368

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets201,792120,533151,566
Total Liabilities249,239120,98952,558
Total Stockholders Equity-47,447-45699,008
Total Debt13,9749,3854,240
Cash and Cash Equivalents17,17138,05212,667

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-56,035-86,231-75,587
Capital Expenditure-840-310-220
Free Cash Flow-56,875-86,541-75,807
Net Income-56931,869-17,368
Net Change in Cash-176,47920,991-24,885

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)119,793.219Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)274,729.193Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)200,455Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)6,625.172Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)17,472.043Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)12,272.202Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)4,111.251Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)12,773.606Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)8,620.992Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)66,099.559Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)151,590.206Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)110,607.156Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.060Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.090Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.030Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
31.71
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-4.52
?Enterprise Value
 (TTM)
: 
415.155M  ?EV/FCF
 (TTM)
: 
-8.14
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-33.97%  ?ROIC
 (TTM)
: 
-29.68%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.02
?P/B
 (TTM)
: 
1.57  ?Current Ratio
 (TTM)
: 
7.82

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Innovative Product Pipeline: Based on the company profile and description, CTMX operates in the biotechnology industry, focusing on novel cancer therapies. This innovation-driven approach positions the company favorably within the high-growth healthcare sector.
  • Strong Revenue Segments: Revenue product and geographic segment data indicate specific categories or regions contributing significantly to revenue, reflecting a diversified or focused income stream that supports financial stability.
  • Positive Earnings Call Insights: Earnings call transcripts highlight management’s confidence in recent results, with key metrics such as revenue or EPS meeting or exceeding expectations, demonstrating operational competence.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates CTMX intrinsic value between $0.59 – $0.90 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate CTMX Intrinsic Value

Common questions about CTMX valuation

Is CytomX Therapeutics, Inc. (CTMX) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for CytomX Therapeutics, Inc. (CTMX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CTMX a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CTMX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CTMX’s P/E ratio?

You can see CTMX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CTMX?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CTMX a good long-term investment?

Whether CTMX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for CytomX Therapeutics, Inc.

  • CytomX Therapeutics, Inc. intrinsic value calculatorEstimate what the business is worth
  • CytomX Therapeutics, Inc. 5-year outlookWhat has to go right, and what could go wrong
CTMX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.98
MarketSnap

Trading Metrics:

Open: 2.02   Previous Close: 2.05
Day Low: 1.99   Day High: 2.16
Year Low: 1.87   Year High: 8.21
Price Avg 50: 2.44   Price Avg 200: 3.63
Volume: 4.854M   Average Volume: 3.794M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

CytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To Shine
13-11-2026 06:31
CytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To Shine
CytomX Therapeutics Q3 Earnings Call Highlights
05-11-2026 22:17
CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials
05-11-2026 06:18
CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14-09-2026 18:01
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CytomX Therapeutics Q2 Earnings Call Highlights
06-08-2026 21:05
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
08-07-2026 13:01
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze CTMX →
    • FindStock Picks / Stock Screener
    • Value · CTMXIntrinsic Value Calculator
    • Invest · CTMXInvestment Case
    • Hold · CTMX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.